RT Journal Article
SR Electronic
T1 Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.27.24312677
DO 10.1101/2024.08.27.24312677
A1 Jiwani, Zishan
A1 Goldberg, Simon B.
A1 Stroud, Jack
A1 Young, Jacob
A1 Curtin, John
A1 Dunne, John D.
A1 Simonsson, Otto
A1 Webb, Christian A.
A1 Carhart-Harris, Robin
A1 Schlosser, Marco
YR 2024
UL http://medrxiv.org/content/early/2024/08/28/2024.08.27.24312677.abstract
AB Introduction Meditation practice and psychedelic use have attracted increasing attention in the public sphere and scientific research. Both methods induce non-ordinary states of consciousness that may have significant therapeutic benefits. Thus, there is growing scientific interest in potential synergies between psychedelic use and meditation practice with some research suggesting that psychedelics may benefit meditation practice. The present study examined individual, psychedelic-related, and meditation-related factors to determine under what conditions meditators perceive psychedelic use as beneficial for their meditation practice.Method Participants (N = 863) who had reported psychedelic use and a regular meditation practice (at least 3 times per week during the last 12 months) were included in the study. To accommodate a large number of variables, machine learning (i.e., elastic net, random forest) was used to analyze the data.Results Most participants (n = 634, 73.5%) found psychedelic use to have a positive influence on their quality of meditation. Twenty-eight variables showed significant zero-order associations with perceived benefits even following a correction. Elastic net had the best performance (R2 = .266) and was used to identify the most important features. Across 53 variables, the model found that greater use of psychedelics, intention setting during psychedelic use, agreeableness, and exposure to N,N-Dimethyltryptamine (N,N-DMT) were most likely to be associated with the perception that psychedelics benefit meditation practice. The results were consistent across several different approaches used to identify the most important variables (i.e., Shapley values, feature ablation).Discussion Results suggest that most meditators found psychedelic use to have a positive influence on their meditation practice, with: 1) regularity of psychedelic use, 2) the setting of intentions for psychedelic use, 3) having an agreeable personality, and 4) reported use of N,N-DMT being the most likely predictors of perceiving psychedelic use as beneficial. Longitudinal designs and randomized trials manipulating psychedelic use are needed to establish causality.Competing Interest StatementOS was a co-founder of Eudelics AB and has once received a small payment from Mindfully Sweden AB for educational content. CAW has received consulting fees from King & Spalding law firm.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received ethical approval from University College London (Project ID: 10043/004) and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data, R code, study items and consent form used in the study are available at the Open Science Framework (https://osf.io/56utj/?view_only=fb526198b6e3492ab90d5a7baffa9ca6) https://osf.io/56utj/?view_only=fb526198b6e3492ab90d5a7baffa9ca6